Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607945 · ClinicalTrials.gov registry record · Phase 1
Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00607945 is a Phase 1 study that has completed, run by Ohio State University. The registered enrollment target is 48 participants.
The verdict
NCT00607945, a Phase 1 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of the study is to see how a dietary oil called conjugated linoleic acid, or CLA, might be useful in combination with diabetes medication. Some studies show that CLA can modestly reduce body weight and body fat. Our research idea is that taking CLA will reduce body weight and body fat without interfering with the diabetes medications' effects on blood sugar.
Interventions
- DRUG Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant
- DIETARY_SUPPLEMENT conjugated linoleic acid (CLA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00607945
The ClinicalTrials.gov registry entry for NCT00607945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant is the first listed.
NCT00607945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00607945 about?
NCT00607945 is a clinical study titled "Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus". The purpose of the study is to see how a dietary oil called conjugated linoleic acid, or CLA, might be useful in combination with diabetes medication. Some studies show that CLA can modestly reduce body weight and body fat. Our research idea is that taking CLA will reduce body weight and body fat wi...
What is the current status of trial NCT00607945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00607945?
The interventions under investigation include: Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant (DRUG), conjugated linoleic acid (CLA) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00607945?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.